Skip to main content
All articles
Heart Health4 min read

What a high hs-CRP result means, and why you retest it

Numia Care TeamOctober 18, 2026
A smiling grey-haired man in a T-shirt printed with a glowing heart

A high hs-CRP result, above 3 mg/L, points to low-grade inflammation, not a diagnosis, and it's worth retesting. Heart-risk guidance averages two results taken about two weeks apart while you're well, and a result above 10 mg/L is set aside and repeated.

C-reactive protein (CRP) is made by your liver when there's inflammation. A high-sensitivity (hs) test reads it accurately below 3 mg/L. In people without symptoms, BC's guideline uses it for one purpose: assessing heart risk. Numia Health, a physician-ordered, at-home blood testing service in Greater Vancouver, includes hs-CRP on its Cardiac / Inflammatory panel.

What does your hs-CRP number mean?

Heart-risk bands come from an American Heart Association and CDC (AHA/CDC) statement:

hs-CRP, mg/LHow it's read for heart risk
Under 1.0Lower relative risk
1.0 to 3.0Average
Above 3.0Higher relative risk
2.0 or moreCanadian guidelines' line at intermediate risk
Above 10Set aside; retest in about 2 weeks
Numia Cardiac panelhs-CRP with apoB, Lp(a) and lipids: $249, HSA eligible

Each band is roughly a third of adults, and treatment decisions stay with your physician (how Canadian guidance uses 2 mg/L).

When should you retest hs-CRP?

CRP peaks about 48 hours after a trigger such as a cold or injury, then falls quickly, so one reading can catch a passing spike. The AHA/CDC statement recommends:

  • Two measurements, about two weeks apart, once you're well, averaged.
  • Above 10 mg/L: set it aside and repeat in two weeks.
  • Still above 10 with no clear cause, or with symptoms: see your physician.

CRP also shifts on its own: in a Canadian study that measured it 15 times over a year in 100 stable adults, most with heart disease, 46% crossed the 2 mg/L line at least once (Bogaty et al., 2013). A second Numia panel two weeks later gives you a steadier number.

Why does the trend matter more than one result?

Because where your level is heading adds to where it is today. In a US study of 10,160 adults with hs-CRP measured about six years apart, people whose level was 3 mg/L or higher both times had the highest risk of heart disease, stroke, heart failure and death over the following years (Parrinello et al., 2015).

That's where a Numia baseline helps. Each Cardiac panel adds a point to your hs-CRP line in the app, beside your lipids (healthy levels), so you can see whether it's settling or staying high.

Where does Numia fit?

Numia Health brings the usual steps (an appointment, a lab visit, a wait, another appointment for results) into one place, which makes a planned Cardiac / Inflammatory panel retest simpler. A licensed Canadian physician approves your requisition online in about three minutes, and a clinician comes to your home in Greater Vancouver for a 10-minute morning draw. Plain-English results reach the Numia app in 7 days, where the Numia Companion, an AI that has read them, answers questions. Out-of-range results are physician-reviewed with next steps, and an optional wellness consultation is available. Numia is an HSA-eligible service.

Frequently asked questions

What does a high hs-CRP result mean?

A high hs-CRP means low-grade inflammation, which can add to heart risk or reflect a recent cold, extra weight, smoking or a condition like arthritis. One result above 3 mg/L is repeated about two weeks later and averaged.

How long should I wait to retest hs-CRP?

About two weeks, once any infection or injury has settled, then average the two, per the AHA/CDC statement. Later retests show your trend, and the Numia app keeps them together.

Is hs-CRP the same as a regular CRP test?

It measures the same protein, but accurately below 3 mg/L, the heart-risk range. BC's guideline asks physicians to specify hs-CRP on the requisition, and Numia's Cardiac panel reports it.

Sources7 references
  1. Bogaty, P., Dagenais, G. R., Joseph, L., Boyer, L., Leblanc, A., Bélisle, P., & Brophy, J. M. (2013). Time variability of C-reactive protein: Implications for clinical risk stratification. PLOS ONE, 8(4), e60759. View source
  2. Gudenkauf, B. M., Jacobsen, A. P., Blumenthal, R. S., Stone, N. J., & Martin, S. S. (2021, September 7). Update in prevention: 2021 Canadian Cardiovascular Society dyslipidemia guidelines. American College of Cardiology. View source
  3. Guidelines and Protocols Advisory Committee. (2018). C-reactive protein and erythrocyte sedimentation rate testing. BC Guidelines. British Columbia Ministry of Health. View source
  4. Marriott, K. A., Stratford, P. W., Verschoor, C. P., Bowdish, D. M. E., Mourtzakis, M., Chopp-Hurley, J. N., Wiebenga, E. G., & Maly, M. R. (2026). Associations of body fat percentage with C-reactive protein levels in Canadian adults with and without osteoarthritis: Findings from the Canadian Longitudinal Study on Aging (CLSA). PLOS ONE, 21(2), e0341604. View source
  5. Numia Health. (n.d.). Cardiac / Inflammatory Panel. Retrieved September 25, 2026, from View source
  6. Parrinello, C. M., Lutsey, P. L., Ballantyne, C. M., Folsom, A. R., Pankow, J. S., & Selvin, E. (2015). Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. American Heart Journal, 170(2), 380–389. View source
  7. Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., III, Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., Rifai, N., Smith, S. C., Jr., Taubert, K., Tracy, R. P., & Vinicor, F. (2003). Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3), 499–511. View source

Last updated October 18, 2026